Allergy Therapeutics PLC
OTC:AGYTF

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
OTC:AGYTF
Watchlist
Price: 0.11 USD Market Closed
Market Cap: $524.3m

Operating Margin

-51.3%
Current
Improving
by 5%
vs 3-y average of -56.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-51.3%
=
Operating Income
£-28.3m
/
Revenue
£55m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-51.3%
=
Operating Income
$-28.3m
/
Revenue
£55m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Allergy Therapeutics PLC
LSE:AGY
706.3m GBP
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
271.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.2B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.1B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.6B EUR
Loading...

Market Distribution

Lower than 95% of companies in United Kingdom
Percentile
5th
Based on 3 579 companies
5th percentile
-51.3%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Allergy Therapeutics PLC
Glance View

Market Cap
524.3m USD
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGYTF Intrinsic Value
0.03 USD
Overvaluation 71%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-51.3%
=
Operating Income
£-28.3m
/
Revenue
£55m
What is Allergy Therapeutics PLC's current Operating Margin?

The current Operating Margin for Allergy Therapeutics PLC is -51.3%, which is above its 3-year median of -56.4%.

How has Operating Margin changed over time?

Over the last 3 years, Allergy Therapeutics PLC’s Operating Margin has decreased from -16.8% to -51.3%. During this period, it reached a low of -72.9% on Dec 31, 2023 and a high of -16.8% on May 30, 2022.

Back to Top